Wuxi STA, a subsidiary of WuXi AppTec, continued its manufacturing expansion march with the opening of another high-potency active pharmaceutical ingredient (HPAPI) production facility in China.
The latest in WuXi’s facilities is located at the company’s Changzhou site in Jiangsu, China, and boasts reactors ranging from 250 liters to 3,000 liters. The new plant also features flow chemistry and milling technology.
The company now has two sites—Changzhou and Shanghai—that will help support WuXi STA's development and manufacturing of HPAPIs. Each of the production sites have multiple high potency processes, R&D labs, kilo labs other technologies.
The Changzhou plant also features the ability to handle linkers, oligonucleotides and peptides for CDMO customers developing therapies made of complex conjugate modalities, the company said.
Earlier this year, WuXi STA said its Waigaoqiao facility near Shanghai passed its first FDA drug product preapproval inspection, and two additional preapproval inspections by China’s regulatory agency, the NMPA.
Back in 2019, WuXi Biologics and WuXi AppTec said they would spend $20 million to build a 60,000-square-meter site near Shanghai to manufacture antibody-drug conjugates as part of its effort to expand production capacity.